U.S. Markets closed

Verona Pharma plc (VNAPF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.76000.0000 (0.00%)
At close: 9:30AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7600
Open0.7600
BidN/A x N/A
AskN/A x N/A
Day's Range0.7600 - 0.7600
52 Week Range0.5700 - 2.0000
Volume100
Avg. Volume0
Market Cap74.981M
Beta (5Y Monthly)0.57
PE Ratio (TTM)N/A
EPS (TTM)-1.9820
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Lisa Deschamps Joins Verona Pharma as Non-Executive Director
    GlobeNewswire

    Lisa Deschamps Joins Verona Pharma as Non-Executive Director

    LONDON and RALEIGH, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces, effective March 1, 2021, Ms. Lisa Deschamps has joined the board as a Non-Executive Director. Ms. Deschamps is Senior Vice President, Chief Business Officer, of Novartis Gene Therapies (GTx) where she is responsible for strategic planning and worldwide commercialization of pipeline and in-market assets across the gene therapy portfolio. This includes managing significant revenue growth targets and profitability margins worldwide. Prior to this role, Ms. Deschamps was the Head of the Global Neuroscience Franchise. During her 25-year career at Novartis, she has successfully brought small molecules, biologics and gene therapies from the clinic to commercialization. Throughout her tenure, Ms. Deschamps has gained significant global and US experience in bringing respiratory and other specialized therapeutic area products to the marketplace. In addition, she has extensive experience in the exploration of potential acquisition and partnering opportunities. “We are delighted to welcome Lisa to the Board,” said Dr. David Ebsworth, Chairperson of Verona Pharma. “Her wealth of leadership, strategic and commercial expertise will be valuable as we progress ensifentrine through Phase 3 trials and prepare for commercialization.” Ms. Deschamps serves on a number of commercial and development executive teams within the Novartis enterprise. She has an MBA in General Management from NYU Stern School of Business and a BBA in marketing from IONA College, Hagan School of Business. For further information, please contact: Verona Pharma plcUS Tel: +1-833-417-0262UK Tel: +44 (0)20 3283 4200Victoria Stewart, Director of Communicationsinfo@veronapharma.com Argot Partners(US Investor Enquiries)Tel: +1 212-600-1902verona@argotpartners.comKimberly Minarovich / Michael Barron Optimum Strategic Communications(International Media and European Investor Enquiries)Tel: +44 (0)203 950 9144verona@optimumcomms.comMary Clark / Eva Haas / Shabnam Bashir About Verona Pharma Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com. Forward-Looking Statements This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

  • Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference
    GlobeNewswire

    Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference

    LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on-demand starting at 7:00 AM ET on Tuesday, March 9, 2021.A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com. Verona Pharma plcUS Tel: +1-833-417-0262UK Tel: +44 (0)20 3283 4200Victoria Stewart, Director of Communicationsinfo@veronapharma.com Argot Partners(US Investor Enquiries)Tel: +1-212-600-1902verona@argotpartners.comKimberly Minarovich / Michael Barron Optimum Strategic Communications(International Media and European Investor Enquiries)Tel: +44 (0)203 950 9144verona@optimumcomms.comMary Clark / Eva Haas / Shabnam Bashir About Verona PharmaVerona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.Forward-Looking StatementsThis press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

  • ACCESSWIRE

    Verona Pharma Plc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Verona Pharma Plc (NASDAQ:VRNA) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 2:00 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.